Evidence map›Paper›PMID 23028829›Full record

ArticlePloS one2012

A symmetric region of the HIV-1 integrase dimerization interface is essential for viral replication.

Erik Serrao, Wannes Thys, Jonas Demeulemeester, Laith Q Al-Mawsawi, Frauke Christ, Zeger Debyser, Nouri Neamati

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. HIV-1 integrase multimerization as a therapeutic target.Current topics in microbiology and immunology · 2015
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Erik SerraoDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, USA.
Wannes Thys
Jonas Demeulemeester
Laith Q Al-Mawsawi
Frauke Christ
Zeger Debyser
Nouri Neamati
KU Leuven · BEUniversity of Southern California · US

Funding

Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
Inhibition of HIV-1 Integrase-LEDGF/P75 InteractionsR21AI081610 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NEAMATI, NOURI · 2009 to 2010
$450k
NCATS NIH HHS UL1 TR000130NIAID NIH HHS R21 AI081610
6 · The paper itself

Abstract

HIV-1 integrase (IN) is an important target for contemporary antiretroviral drug design research. Historically, efforts at inactivating the enzyme have focused upon blocking its active site. However, it has become apparent that new classes of allosteric inhibitors will be necessary to advance the antiretroviral field in light of the emergence of viral strains resistant to contemporary clinically used IN drugs. In this study we have characterized the importance of a close network of IN residues, distant from the active site, as important for the obligatory multimerization of the enzyme and viral replication as a whole. Specifically, we have determined that the configuration of six residues within a highly symmetrical region at the IN dimerization interface, composed of a four-tiered aromatic interaction flanked by two salt bridges, significantly contributes to proper HIV-1 replication. Additionally, we have utilized a quantitative luminescence assay to examine IN oligomerization and have determined that there is a very low tolerance for amino acid substitutions along this region. Even conservative residue substitutions negatively impacted IN multimerization, resulting in an inactive viral enzyme and a non-replicative virus. We have shown that there is a very low tolerance for amino acid variation at the symmetrical dimeric interface region characterized in this study, and therefore drugs designed to target the amino acid network detailed here could be expected to yield a significantly reduced number of drug-resistant escape mutations compared to contemporary clinically-evaluated antiretrovirals.

Indexed as

MutationAllosteric RegulationAllosteric SiteAmino Acid SequenceAmino Acid SubstitutionEscherichia coliHIV-1HIV IntegraseModels, MolecularMolecular Sequence DataProtein MultimerizationProtein Structure, TertiaryRecombinant ProteinsVirus ReplicationHIV Integrasep31 integrase protein, Human immunodeficiency virus 1Recombinant Proteins

Identifiers

PMID23028829
PMCPMC3445459
OpenAlexW2033638553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.